Masimo [MASI] vs Boston Scientific [BSX] Detailed Stock Comparison
Masimo
NASDAQ
Loading...
Boston Scientific
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Masimo wins in 4 metrics, Boston Scientific wins in 15 metrics, with 0 ties. Boston Scientific appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Masimo | Boston Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 129.16 | 60.80 | Boston Scientific |
| Price-to-Book Ratio | 7.82 | 6.78 | Boston Scientific |
| Debt-to-Equity Ratio | 61.58 | 53.09 | Boston Scientific |
| PEG Ratio | 32.36 | 36.83 | Masimo |
| EV/EBITDA | 55.26 | 34.85 | Boston Scientific |
| Profit Margin (TTM) | -21.32% | 13.55% | Boston Scientific |
| Operating Margin (TTM) | 17.12% | 18.63% | Boston Scientific |
| EBITDA Margin (TTM) | 17.12% | 18.63% | Boston Scientific |
| Return on Equity | -22.37% | 11.55% | Boston Scientific |
| Return on Assets (TTM) | 1.84% | 5.39% | Boston Scientific |
| Free Cash Flow (TTM) | $145.30M | $2.37B | Boston Scientific |
| 1-Year Return | 24.66% | 31.85% | Boston Scientific |
| Price-to-Sales Ratio (TTM) | 3.79 | 8.23 | Masimo |
| Enterprise Value | $8.50B | $163.98B | Boston Scientific |
| EV/Revenue Ratio | 3.95 | 8.87 | Masimo |
| Gross Profit Margin (TTM) | 62.90% | 67.65% | Boston Scientific |
| Revenue per Share (TTM) | $40 | $13 | Masimo |
| Earnings per Share (Diluted) | $-5.08 | $1.69 | Boston Scientific |
| Beta (Stock Volatility) | 1.21 | 0.66 | Boston Scientific |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Masimo vs Boston Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Masimo | 1.32% | 6.32% | -3.86% | -0.34% | -14.69% | -8.72% |
| Boston Scientific | -0.94% | 0.03% | -0.30% | -1.61% | -2.07% | 15.43% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Masimo | 24.66% | -1.19% | -29.80% | 270.50% | 555.88% | 668.58% |
| Boston Scientific | 31.85% | 145.53% | 168.46% | 531.01% | 1,713.18% | 274.35% |
Performance & Financial Health Analysis: Masimo vs Boston Scientific
| Metric | MASI | BSX |
|---|---|---|
| Market Information | ||
| Market Cap | $8.16B | $152.25B |
| Market Cap Category | Mid cap | Large cap |
| 10 Day Avg. Volume | 1,111,551 | 5,978,470 |
| 90 Day Avg. Volume | 719,827 | 7,119,910 |
| Last Close | $153.87 | $103.17 |
| 52 Week Range | $107.98 - $194.88 | $76.60 - $108.94 |
| % from 52W High | -21.04% | -5.30% |
| All-Time High | $305.21 (Nov 15, 2021) | $108.94 (Jul 23, 2025) |
| % from All-Time High | -49.59% | -5.30% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.23% |
| Quarterly Earnings Growth | 2.21% | 1.46% |
| Financial Health | ||
| Profit Margin (TTM) | -0.21% | 0.14% |
| Operating Margin (TTM) | 0.17% | 0.19% |
| Return on Equity (TTM) | -0.22% | 0.12% |
| Debt to Equity (MRQ) | 61.58 | 53.09 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $19.20 | $15.14 |
| Cash per Share (MRQ) | $2.75 | $0.36 |
| Operating Cash Flow (TTM) | $176.60M | $4.28B |
| Levered Free Cash Flow (TTM) | $92.86M | $2.94B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | $0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Masimo vs Boston Scientific
| Metric | MASI | BSX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 129.16 | 60.80 |
| Forward P/E | 32.36 | 36.83 |
| PEG Ratio | 32.36 | 36.83 |
| Price to Sales (TTM) | 3.79 | 8.23 |
| Price to Book (MRQ) | 7.82 | 6.78 |
| Market Capitalization | ||
| Market Capitalization | $8.16B | $152.25B |
| Enterprise Value | $8.50B | $163.98B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.95 | 8.87 |
| Enterprise to EBITDA | 55.26 | 34.85 |
| Risk & Other Metrics | ||
| Beta | 1.21 | 0.66 |
| Book Value per Share (MRQ) | $19.20 | $15.14 |
Financial Statements Comparison: Masimo vs Boston Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MASI | BSX |
|---|---|---|
| Revenue/Sales | $372.00M | $4.66B |
| Cost of Goods Sold | $138.00M | $1.45B |
| Gross Profit | $234.00M | $3.21B |
| Research & Development | $33.90M | $443.00M |
| Operating Income (EBIT) | $80.70M | $937.00M |
| EBITDA | $90.70M | $1.23B |
| Pre-Tax Income | $68.40M | $805.00M |
| Income Tax | $21.20M | $133.00M |
| Net Income (Profit) | $-170.70M | $672.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MASI | BSX |
|---|---|---|
| Cash & Equivalents | $130.80M | $725.00M |
| Total Current Assets | $1.18B | $7.34B |
| Total Current Liabilities | $546.50M | $5.06B |
| Long-Term Debt | $657.70M | $10.93B |
| Total Shareholders Equity | $946.40M | $22.45B |
| Retained Earnings | $1.32B | $3.35B |
| Property, Plant & Equipment | $183.60M | $448.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MASI | BSX |
|---|---|---|
| Operating Cash Flow | $62.60M | $513.00M |
| Capital Expenditures | $17.00M | $-187.00M |
| Free Cash Flow | $27.00M | $277.00M |
| Debt Repayment | $-78.80M | $-1.31B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | MASI | BSX |
|---|---|---|
| Shares Short | 3.27M | 19.57M |
| Short Ratio | 6.08 | 2.65 |
| Short % of Float | 0.09% | 0.01% |
| Average Daily Volume (10 Day) | 1,111,551 | 5,978,470 |
| Average Daily Volume (90 Day) | 719,827 | 7,119,910 |
| Shares Outstanding | 53.60M | 1.47B |
| Float Shares | 45.31M | 1.48B |
| % Held by Insiders | 0.08% | 0.00% |
| % Held by Institutions | 1.02% | 0.93% |
Dividend Analysis & Yield Comparison: Masimo vs Boston Scientific
| Metric | MASI | BSX |
|---|---|---|
| Last 12-Month Dividend | $0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | $0.00 | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | $0.00 | N/A |
| Ex-Dividend Date | N/A | N/A |